Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 27, 1992 - Issue 10
Submit an article Journal homepage
137
Views
25
CrossRef citations to date
0
Altmetric
Original Article

Disposition of Mesalazine from Mesalazine-Delivering Drugs in Patients with Inflammatory Bowel Disease, with and without Diarrhoea

M. C. M. Rijk Dept. of Gastrointestinal and Liver Diseases, University Hospital Nijmegen, Nijmegen, The Netherlands
,
A. vanSchaik Dept. of Gastrointestinal and Liver Diseases, University Hospital Nijmegen, Nijmegen, The Netherlands
&
J. H. M. Van Tongeren Dept. of Gastrointestinal and Liver Diseases, University Hospital Nijmegen, Nijmegen, The Netherlands
Pages 863-868 | Received 23 Jan 1992, Accepted 11 May 1992, Published online: 08 Jul 2009

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Glen A Doherty & Mark A Peppercorn. (2009) Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease. Clinical and Experimental Gastroenterology 2, pages 139-147.
Read now
K. W. Schroeder. (2002) Role of Mesalazine in Acute and Long-Term Treatment of Ulcerative Colitis and Its Complications. Scandinavian Journal of Gastroenterology 37:236, pages 42-47.
Read now

Articles from other publishers (23)

Anand Kumar, Vinayak Shenoy, Megan C. Buckley, Laura Durbin, James Mackey, Anjali Mone & Arun Swaminath. (2022) Endoscopic Disease Activity and Biologic Therapy Are Independent Predictors of Suboptimal Bowel Preparation in Patients with Inflammatory Bowel Disease Undergoing Colonoscopy. Digestive Diseases and Sciences 67:10, pages 4851-4865.
Crossref
Luc J. J. Derijks, Dennis R. Wong, Daniel W. Hommes & Adriaan A. van Bodegraven. (2018) Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clinical Pharmacokinetics 57:9, pages 1075-1106.
Crossref
A. M. Haase, T. Gregersen, L. A. Christensen, J. Agnholt, J. F. Dahlerup, V. Schlageter & K. Krogh. (2016) Regional gastrointestinal transit times in severe ulcerative colitis. Neurogastroenterology & Motility 28:2, pages 217-224.
Crossref
Michitaka Goto, Yasuhiro Okamoto, Magobei Yamamoto & Hatsumi Aki. (2001) Anti-inflammatory effects of 5-aminosalicylic acid conjugates with chenodeoxycholic acid and ursodeoxycholic acid on carrageenan-induced colitis in guinea-pigs. Journal of Pharmacy and Pharmacology 53:12, pages 1711-1720.
Crossref
A Barney Hawthorne. (2009) A Review of Multimatrix System (MMX) Mesalazine in the Management of Ulcerative Colitis. Clinical Medicine. Therapeutics 1, pages CMT.S38.
Crossref
Nahor Haddish-Berhane, Chell Nyquist, Kamyar Haghighi, Carlos Corvalan, Ali Keshavarzian, Osvaldo Campanella, Jenna Rickus & Ashkan Farhadi. (2006) A multi-scale stochastic drug release model for polymer-coated targeted drug delivery systems. Journal of Controlled Release 110:2, pages 314-322.
Crossref
Jan Hessels, Harry H. M. Eidhof, Jan Steggink, Wilfried W. H. Roeloffzen, Kalung Wu, Guy Tan, Jan van de Stadt & Leo van Bergeijk. (2003) Assessment of Hypolactasia and Site-Specific Intestinal Permeability by Differential Sugar Absorption of Raffinose, Lactose, Sucrose and Mannitol. Clinical Chemistry and Laboratory Medicine 41:8.
Crossref
W. J. Sandborn & S. B. Hanauer. (2003) The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Alimentary Pharmacology & Therapeutics 17:1, pages 29-42.
Crossref
R. J. Makins & R. E. Cowan. (2002) 5‐amino‐salicylate in the management of inflammatory bowel disease. Colorectal Disease 3:4, pages 218-222.
Crossref
A. Qasim, J. Seery & C.A. O'Morain. (2001) 5-Aminosalicylates in inflammatory bowel: disease: Choosing choosing the right dose. Digestive and Liver Disease 33:5, pages 393-398.
Crossref
Matthias Schwab & Ulrich Klotz. (2001) Pharmacokinetic Considerations in the Treatment of Inflammatory Bowel Disease. Clinical Pharmacokinetics 40:10, pages 723-751.
Crossref
J. Keller & P. Layer. 2001. Chronisch entzündliche Darmerkrankungen. Chronisch entzündliche Darmerkrankungen 123 134 .
Delyth Clemett & Anthony Markham. (2000) Prolonged-Release Mesalazine*. Drugs 59:4, pages 929-956.
Crossref
F. N. Hussain, R. A. Ajjan & S. A. Riley. (2000) Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. British Journal of Clinical Pharmacology 49:4, pages 323-330.
Crossref
Ulrich Klotz. (1999) Pharmakokinetische Daten für verschiedene 5-Aminosalicylsäure- und BudesonidpräparatePharmacokinetic properties of various preparations of 5-Aminosalicylic acid (5-ASA) and budesonide. Medizinische Klinik 94:S1, pages 16-22.
Crossref
Stig Bondesen. (1997) INTESTINAL FATE OF 5-AMINOSALICYLIC ACID: REGIONAL AND SYSTEMIC KINETIC STUDIES IN RELATION TO INFLAMMATORY BOWEL DISEASE. Pharmacology & Toxicology 81, pages 1-30.
Crossref
Stephen B. Hanauer. (1996) Inflammatory Bowel Disease. New England Journal of Medicine 334:13, pages 841-848.
Crossref
E. ELTON & S. B. HANAUER. (2007) Review article: The medical management of Crohn's disease. Alimentary Pharmacology & Therapeutics 10:1, pages 1-22.
Crossref
Claudia S. Leopold & David R. Friend. (1995) In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery. Journal of Pharmacokinetics and Biopharmaceutics 23:4, pages 397-406.
Crossref
J. LAROUCHE, J. MORAIS, M. PICARD, C. LAMBERT, J. SPÉNARD, H. LANDRIAULT, G. KENNEDY & P. POITRAS. (2007) Release of 5‐ASA from Pentasa in patients with Crohn's disease of the small intestine. Alimentary Pharmacology & Therapeutics 9:3, pages 315-320.
Crossref
J Rhodes & G A Coles. (1995) An alternative view of 5-ASA formulations.. Gut 36:4, pages 639-640.
Crossref
G Jarnerot. (1994) New salicylates as maintenance treatment in ulcerative colitis.. Gut 35:9, pages 1155-1158.
Crossref
I. Bjarnason & A. J. Macpherson. (1993) Delivery, safety and efficacy of 5-aminosalicylate preparations. InflammoPharmacology 2:3, pages 277-287.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.